Esophageal Cancer Market Poised for 6% CAGR Growth Through 2036, Driven by ADC and Immunotherapy Innovation
Key Insights
The global esophageal cancer (search) market across seven major markets was valued at USD 1.3 billion in 2025 and is projected to grow at a 6% CAGR through 2036, according to a DelveInsight (search) report.
Approximately 79,000 incident cases of esophageal cancer (search) were reported across the 7MM in 2025, with the United States accounting for the largest treatment market share.
Emerging therapies including antibody-drug conjugates such as Telisotuzumab adizutecan, bispecific antibodies like Zanidatamab, and next-generation immunotherapies are expected to reshape the treatment landscape.
The esophageal cancer (search) treatment market is entering a period of significant transformation, with the global market across the seven major markets (7MM) — the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan — valued at USD 1.3 billion in 2025 and projected to grow at a compound annual growth rate (CAGR) of 6% through 2036, according to a newly published report from DelveInsight (search).
The report highlights that the United States accounted for the largest esophageal cancer (search) treatment market share in 2025, with total incident cases across the 7MM reaching approximately 79,000. Within the U.S., non-squamous cell esophageal cancer incidence was higher at approximately 14,000 cases compared to roughly 8,000 cases of squamous cell esophageal cancer.
Pipeline Innovation Driving Market Transformation
A robust pipeline of investigational therapies is expected to be the primary catalyst for market growth. Key candidates span multiple therapeutic classes, including antibody-drug conjugates (ADCs), bispecific antibodies, and next-generation targeted therapies.
Among the most closely watched candidates is AbbVie (search)'s Telisotuzumab adizutecan (Temab-A), an investigational ADC targeting c-Met (search), a receptor commonly overexpressed in various solid malignancies including gastroesophageal adenocarcinoma. The therapy is designed to deliver cytotoxic agents directly to tumor cells with greater precision and is currently being investigated across multiple tumor types, including non-small cell lung cancer, colorectal cancer, and gastroesophageal adenocarcinoma.
Zanidatamab, being co-developed by Zymeworks and Jazz Pharmaceuticals, represents another promising approach. This advanced-stage investigational therapy targets multiple HER2 (search)-expressing malignancies and has received Fast Track Designation from the FDA for use in combination with standard chemotherapy as a first-line treatment for gastroesophageal adenocarcinoma. The ongoing Phase III HERIZON-GEA-01 study is evaluating zanidatamab alongside chemotherapy, with or without the PD-1 inhibitor tislelizumab, in patients with metastatic HER2-positive GEA.
Merck (search) and Daiichi Sankyo's Ifinatamab deruxtecan (MK-2400), a novel ADC composed of a humanized anti-B7-H3 (search) IgG1 monoclonal antibody linked to a topoisomerase I inhibitor payload, is also advancing through clinical development. Meanwhile, Merck and Eisai are co-developing Lenvatinib (LENVIMA), an oral multi-targeted kinase inhibitor that blocks VEGFR1-3, FGFR1-4, PDGFRα, KIT, and RET, in combination with KEYTRUDA for metastatic esophageal carcinoma in a Phase III trial.
Additional pipeline candidates include Amgen's Bemarituzumab, an FGFR2b (search)-targeted therapy; Pfizer's PF-08046033; Macrogenics' MGC026; and Ragistomig from I-Mab and ABL Bio.
Immunotherapy Reshapes the Standard of Care
The advent of immune checkpoint inhibitors has already reshaped the treatment paradigm for advanced and metastatic esophageal cancer (search). PD-1/PD-L1 (search) inhibitors including pembrolizumab (KEYTRUDA), nivolumab (OPDIVO), tislelizumab (TEVIMBRA), and durvalumab (IMFINZI) have delivered meaningful improvements in patient survival.
Several recent regulatory milestones underscore this momentum. In November 2025, the FDA approved durvalumab (IMFINZI, AstraZeneca) with FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin, and docetaxel) as neoadjuvant and adjuvant treatment, followed by single-agent durvalumab, for adults with resectable gastric or gastroesophageal junction adenocarcinoma. That same month, five-year follow-up data from the Phase III KEYNOTE-590 study confirmed that pembrolizumab combined with chemotherapy demonstrated sustained long-term survival benefit in advanced esophageal cancer (search), with improved overall survival and progression-free survival versus chemotherapy alone.
In March 2025, tislelizumab (TEVIMBRA) received FDA approval in combination with chemotherapy for the first-line treatment of unresectable or metastatic esophageal squamous cell carcinoma with PD-L1 (search) expression, further expanding frontline immunotherapy options.
Targeted Therapies and Precision Medicine
The report emphasizes that biomarker-guided therapies are playing an increasingly important role in treatment selection. Among approved targeted therapies, trastuzumab (HERCEPTIN/OGIVRI) is used with chemotherapy as first-line treatment for metastatic esophageal adenocarcinoma, while trastuzumab deruxtecan (ENHERTU) is also approved in this setting. Ramucirumab (CYRAMZA) combined with paclitaxel remains an established option for patients with advanced gastroesophageal or gastroesophageal junction adenocarcinoma following disease progression on initial therapy.
Aparna Thakur, project manager of forecasting at DelveInsight (search), noted that emerging therapies including HER2 (search)-targeted agents such as Zanidatamab, FGFR2b (search)-targeted therapies such as Bemarituzumab, and antibody-drug conjugates like Telisotuzumab adizutecan "are expected to witness gradual but steady uptake over the forecast period." Thakur added that "their adoption will largely depend on clinical trial outcomes, regulatory approvals, and the expansion of biomarker testing to identify eligible patient populations."
Market Drivers and Future Outlook
Key factors propelling market growth include the rising incidence of esophageal adenocarcinoma and squamous cell carcinoma driven by aging populations, obesity, GERD, tobacco use, and alcohol consumption. Advances in multimodal treatment approaches combining surgery, chemotherapy, radiation therapy, and immunotherapy have contributed to improved patient survival, while progress in molecular diagnostics has enhanced detection of actionable genetic alterations.
The anticipated launch of these emerging therapies is expected to offer new standards of care and unlock opportunities for medical innovation and economic growth across the 7MM through 2036.